Fig. 3
Effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and B7-1 on immunization with genetically modified embryonic fibroblasts and naked DNA
(A) Mice (n = 10/group) were injected subcutaneously with 2 × 106 fibroblasts expressing MAGE-1 (◇), MAGE-1 and GM-CSF (○), MAGE-1 and B7-1 (△), GM-CSF (■), B7-1 (◆), or mock-infected fibroblasts (□), and challenged 2 weeks later with 2 × 106 B16-MAGE-1 melanoma cells. (B through D) Mice (n = 5/group) were injected subcutaneously with 2.5 × 106 fibroblasts expressing MAGE-3 (◇), MAGE-3 and GM-CSF (○), MAGE-3 and B7-1 (△), GM-CSF (■), B7-1 (◆), or mock-infected fibroblasts (□). Animals were challenged subcutaneously 2 weeks later with 2.5 × 106 B16-MAGE-3 (B), 1 × 106 B16-MAGE-3 (C), or 1 × 106 B16 tat (D) melanoma cells. (E) Mice (n = 10/group) were injected twice separated by 2 weeks with 0.9% saline (□), 100 µg of pCMV-MAGE-1 (◇), 30 jug of pCMV-MAGE-1 (○), 30 µg of pCMV-MAGE-1 and 100 ◯g of pCMV-GMCSF (△), or 30 µg of pCMV-MAGE-1 and 100 µg of pCMV-B7-1 (■). Animals were challenged 2 weeks after the second immunization with 2.5 × 106 B16-MAGE-1 cells.